966 related articles for article (PubMed ID: 24028614)
1. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
2. Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide.
O'Donnell A; Moollan A; Baneham S; Ozgul M; Pabari RM; Cox D; Kirby BP; Ramtoola Z
J Pharm Pharmacol; 2015 Apr; 67(4):525-36. PubMed ID: 25515568
[TBL] [Abstract][Full Text] [Related]
3. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
4. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
5. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
6. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
8. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
9. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
12. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.
Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S
Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
15. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
16. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
17. Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination.
Osman R; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
Int J Pharm; 2011 Apr; 408(1-2):257-65. PubMed ID: 21335080
[TBL] [Abstract][Full Text] [Related]
18. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
Win KY; Feng SS
Biomaterials; 2005 May; 26(15):2713-22. PubMed ID: 15585275
[TBL] [Abstract][Full Text] [Related]
19. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
20. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
